At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 30 enrolled
Drug / intervention
Rucaparib +2 moredrug
Likely dose
Rucaparib 600mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label, Non-Randomized Multisite Phase II Trial Combining Bevacizumab, Atezolizumab and Rucaparib for the Treatment of Previously Treated Recurrent and Progressive Endometrial Carcinoma
In Brief
A Phase 2 clinical trial evaluating Rucaparib, Bevacizumab, and 1 other intervention for Endometrial Cancer and Uterine Carcinosarcoma. Completed, enrolled 30 participants across 3 sites.
Detailed Summary
To demonstrate the efficacy and safety of the combination of rucaparib, bevacizumab and atezolizumab in recurrent, progressive endometrial carcinoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEndometrial Cancer, Uterine Carcinosarcoma
CountriesUnited States
CollaboratorsGenentech, Inc., Clovis Oncology, Inc.
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedOct 2018
Enrollment StartJul 2019
Primary CompletionMar 2023
Study CompletionMar 2026
TodayJul 2026
First PostedOct 3, 2018
Enrollment StartJul 19, 2019
Primary CompletionMar 30, 2023
Study CompletionMar 10, 2026
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 7.7 years ago
Interventions
Rucaparibdrug
Rucaparib 600mg orally twice daily by continuous dosing
Bevacizumabdrug
15mg/kg IV on day 1 of every cycle
Atezolizumabdrug
1,200mg IV on day 1 of every cycle